Industry news that matters to you.  Learn more

PrognosDx Health and Accium BioSciences Enter Into Collaborative and Research Agreement to Develop Clinical Tests Based on Histone Biomarkers

Reading time: 2 – 4 minutes

PrognosDx Health, a pioneering company in cancer epigenetics, announced today that Dr. Jeffrey L. Wolf has joined its scientific advisory board. An expert in multiple myeloma and other hematopoietic malignancies, Dr. Wolf also specializes in bone marrow transplantation for treatment of a variety of cancers. Dr. Wolf is the Director of the Multiple Myeloma Program in the Division of Hematology and Oncology at the Helen Diller Family Comprehensive Cancer Center and a Clinical Professor of Medicine at UCSF.

It was also announced that PrognosDx Health and Accium BioSciences (Seattle, Washington) have entered into a collaboration agreement aimed at co-developing and commercializing a series of high-value predictive histone biomarker tests. The collaboration combines the expertise and breakthrough epigenetic platform technology of PrognosDx with the accelerator mass spectrometry (AMS) platform of Accium BioSciences.

AMS is an ultrasensitive detection platform used in Phase 1 clinical studies of new chemical entities. Currently, five of the top 20 pharmaceutical companies are working with Accium BioSciences to overcome challenges they face in clinical development of novel drugs. Accium BioSciences provides AMS capabilities and expertise in a GLP-compliant environment, reporting the pharmacologic properties of novel drugs under investigation at clinical sites around the world.

Accium BioSciences is also pioneering the use of AMS in a range of diagnostic tests with potential utility in personalized medicine. The company is currently using AMS to investigate pharmacologic and pharmacodynamic endpoints of Merck’s Temodar in glioblastoma multiforme (GBM) patients, providing 14C-methylation measurements of tumor DNA after 14C-Temodar administration. The purpose of the study is to identify pharmacologic or pharmacodynamic endpoints that may be predictive of response to therapy in individual patients. The ultimate aim is to identify poor-responders to Temodar early on so GBM patients can be placed on treatments tailored to their condition.

The study is part of a collaboration with The Ben & Catherine Ivy Center for Advanced Brain Tumor Treatment, led by Dr. Greg Foltz, at Swedish Medical Center in Seattle, Washington.

PrognosDx intends to leverage Accium’s expertise and capabilities to advance its Epigenetic biomarkers to the clinic and to support cancer drug resistance, drug efficacy and toxicity studies. Accium BioSciences is committed to providing resources and expertise in proof-of-principle investigations involving therapeutic response prediction and resistance to treatment.

Dr. Ali Arjomand, President and Chief Operating Officer of Accium BioSciences, explained: “We are very much intrigued by the core intellectual property behind the platform technology which has exclusively been licensed to PrognosDx as well as the potential medical applications it may produce for cancer treatment. We have identified specific studies that would help further define the developmental direction of various diagnostic tests and the potential benefits they may provide to specific patient populations.”

Source: Business Wire